Rejuvenate Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Rejuvenate Bio , a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
- Rejuvenate Bio , a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
- “We’re excited to share data at ASGCT 2024 on our RJB-0402 gene therapy which targets key disease-mediating pathways in arrhythmogenic cardiomyopathy (ACM),” said Noah Davidsohn, PhD., Chief Scientific Officer at Rejuvenate Bio.
- “ACM is an inherited disease caused by mutations in one of several genes encoding desmosomal proteins, and there is an urgent need for better treatment options.
- ET on the presentation day, Wednesday May 8, 2024.